Respibron is an immunomodulator based on bacterial lysate that increases the body’s resistance to infections by increasing the amount of serum and secretory antibodies, activating cellular and humoral factors of non-specific immunity. This leads to a reduction in the incidence of and severity of occurrence of respiratory infections, prevents the need for antibiotics. Respibron has a dual mechanism of action: activates non-specific resistance (rapid protection within 2-4 weeks from the start of taking Respibron) due to membrane antigens that are part of the drug, by activating dendritic cells, neutrophils, macrophages and NK cells; inducing phagocytosis and cell lysis by stimulating macrophage adhesion on bacteria; activates specific immunity (long-term protection for several years) by increasing the level of IL-2 production, specific serum IgA, IgG, IgM and slgA, activation of effector CD4 and CD8 T-lymphocytes, activation of B-lymphocytes.
Composition and form of release Respibron
Main active ingredients: bacteria Haemophilus influenzae, Streptococcus (Diplococcus) pneumoniae, Klebsiella pneumoniae and ozaenae, Staphylococcus aureus, Streptococcus pyogenes and viridans, Neisseria catarrhalis.
Auxiliary components: colloidal silicon (hydrated, microcrystalline cellulose, dibasic calcium phosphate, magnesium stearate, ammonium glycerizinate, menthol powder essence.
The drug is sold in tablets, each of which contains 7 mg of a complex of bacteria in the form of a lyophilisate.
Respibron belongs to a group of drugs that are used in the treatment of inflammatory and infectious diseases of the respiratory tract.
The active components of the drug contain a lyophilisate of bacteria that usually cause infectious diseases of the respiratory tract, including bacteria of streptococci, hemophilic influenza, Klebsiella, staphylococcus, moraxella.
With prolonged use, the drug is able to stimulate the defenses of the human body, activating the immune system. As a result, the duration and intensity of the disease decreases, the risks of exacerbation of chronic diseases decrease, and the likelihood of the body’s need for antibacterial drugs decreases.
This effect is due to the ability of the drug to activate the cellular and humoral responses of the mucous membranes that cover the respiratory tract and other immunocompetent structures in the human body.
Respibron is used in the complex therapy of inflammatory diseases of the respiratory tract as an immunomodulator.
The use of this drug prevents the occurrence of recurrent infections of the respiratory tract and severe infectious exacerbations of chronic bronchitis, tracheitis, tracheobronchitis, bronchitis, bronchiectasis, COPD.
Also used as a concomitant agent in the treatment of acute respiratory infections – for influenza, rhinitis, pharyngitis, nasopharyngitis, tonsillitis, sinusitis, laryngitis, epiglotitis, sore throat.
The drug in question is contraindicated for use in cases where the patient has severe hypersensitivity (allergy) to the main or one of the auxiliary components.
It is not recommended to use it together with antitussives.
Used in pediatrics since 2 years.
Application during pregnancy and lactation
This drug is contraindicated in pregnant women.
If it is necessary to take the drug during breastfeeding, lactation is suspended.
Method of administration and dosage
The drug is used in the treatment of colds in the respiratory tract. The tablet dissolves under the tongue, within 1-2 minutes.
- for prophylaxis or complex therapy: 1 tablet a day on an empty stomach for 10 consecutive days a month (the minimum course is 10 days, then repeat after 20 days);
- in the treatment of exacerbations: 1 tablet per day on an empty stomach until the symptoms disappear (the minimum course is 10 days, but not more than 30).
If the child cannot take the drug himself, the tablet can be crushed and placed in the child’s mouth.
In the case of concomitant administration with antibiotics, the drug is recommended to be used from the very beginning of treatment.
Patients with renal or hepatic insufficiency do not need dosage adjustment.
Overdose cases were not observed.
No complications are expected in case of an overdose.
The use of this drug can cause adverse reactions, such as, in particular:
- allergic urticaria, itching, rash;
- nausea, vomiting, diarrhea, angioedema, bronchospasm;
- peripheral edema, shortness of breath, headache;
- increased fatigue, fever.
If side effects occur, the drug should be discontinued, symptomatic therapy should be undertaken, consult a doctor and the treatment regimen should be adjusted.
Storage conditions and periods Respibron
The shelf life is 3 years.
The storage temperature should not exceed 25 ° C.